The biotech company reported promising study results along with clinical partner Merck (NYSE: MRK) that could revolutionize disease treatment. On Tuesday morning, though, news that November inflation figures weren't as bad as some had expected sent the Nasdaq soaring, with futures contracts rising 4% just before the market opened. Moderna (NASDAQ: MRNA) has been looking to build on the foundation that its COVID-19 vaccine success brought it, and favorable study results suggest that it could have another path toward longer-term growth in the immediate future.